In the EU,<unk>  is indicated as adjunctive therapy to preparations of levodopa/ DOPA decarboxylase inhibitors (DDCI) in adults with Parkinson's disease and end-of-dose motor fluctuations who cannot be stabilised on those combinations. In the US,<unk>  is indicated as adjunctive treatment to levodopa/carbidopa in patients with Parkinson's disease (PD) experiencing "off" episodes. The COMT inhibitor<unk>  is used as an additive to a combination of levodopa and a DOPA decarboxylase inhibitor to treat patients with Parkinson's disease experiencing end-of-dose motor fluctuations, if they cannot be stabilised with this drug combination.
Opicapone
Epoetin alfa
Epoetin beta
Lactitol
Retinol
Eutropoflavin
Tricresyl phosphate
Photoanethole